Travere Therapeutics, Inc. - Common Stock (TVTX)

Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026.

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX).

The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.

The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.

The company is nearing a highly anticipated approval for a kidney disease drug.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.

Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker.